

Changes to the acute lymphoblastic leukaemia program

Following a review of Services Australia's administration of the Pharmaceutical Benefits Scheme, there will be a change to the way health professionals can apply for dasatinib (20 mg tablet; 50 mg tablet; 70 mg tablet; 100 mg tablet) to treat patients with acute lymphoblastic leukaemia using the Online PBS Authorities system (the system).

Health professionals are required to include a copy of the pathology report when submitting initial authority applications for approval via the system. This evidentiary addition may delay the assessment response as a Services Australia officer is required to review all applications and attachments (process known as a Full Assessment).

When assessed, an outcome notification will be sent directly to the health professionals Health Professional Online Service (HPOS) mailbox.

All other medications used to treat acute lymphoblastic leukaemia, will be available for approval via the Online PBS Authorities system early next year.

For more information about the **Online PBS Authorities system** visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the **Health Professional Education Resources** website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>